BioSpace News Archive

Abeona Therapeutics Inc. today announced that information about the company’s ABO-102 pivotal Transpher A study in Sanfilippo syndrome type A (MPS IIIA) will be presented at the 14th International Congress of Inborn Errors of Metabolism (ICIEM).

Science 37 Holdings, Inc. has published new data suggesting that the clinical research industry has reached a pivotal shift in the way that clinical trials are conducted, as Sponsors and CROs report they plan to run more agile (or hybrid) clinical trials in 2022 than traditional, site-based studies.

OWP Pharmaceuticals, Inc. is a privately held, commercial-stage neuroscience specialty pharmaceutical company, dedicated to developing and commercializing novel oral liquid formulations.

Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients’ unmet needs and solve therapeutic problems, announced today that the management team will participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference from November 29th to December 2nd.

CoImmune, Inc. announced a research collaboration with Yeda Research and Development Company Ltd., the commercial arm of the Weizmann Institute of Science, to evaluate the applications of the Synthetic Immune Niche technology, developed by Weizmann Institute’s researchers to enhance the expansion and function of human cytokine induced killer cells expressing chimeric antigen receptors.

Fulcrum Therapeutics, Inc. today announced the appointment of Sonja L. Banks to the company’s board of directors, effective December 8.

Pasithea Therapeutics Corp., a novel biotechnology company focused on the research and discovery of new and effective treatments for psychiatric and neurological disorders, announced that its wholly owned subsidiary, Pasithea Clinics, commenced clinical operations, offering in-home intravenous ketamine therapy to patients suffering from treatment-resistant mental health issues.

Sight Sciences, Inc., an eyecare technology company focused on creating innovative solutions intended to transform standards of care and improve patients’ lives, announced publication in Clinical Ophthalmology of favorable data showing that microinvasive glaucoma surgery using the OMNI® Surgical System suppressed daily fluctuations in intraocular pressure – a meaningful and independent risk factor for the progression of glaucoma.

BiomX Inc. today announced upcoming presentations at the Jefferies London Healthcare Conference on November 18 - 19, 2021 and Phage Futures Congress Europe on November 23 - 24, 2021.

Enteris BioPharma, Inc., a biotechnology company developing innovative drug products based on its proprietary delivery technologies, and a wholly-owned subsidiary of SWK Holdings Corporation, announced the publication of a new article entitled, “The 505 Pathway – Pharma’s ‘Goldilocks’ Opportunity.”